Symbols / GLMD Stock $0.64 +2.15% Galmed Pharmaceuticals Ltd.
GLMD (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Ratings
Current target
$0.63
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-04 | down | Maxim Group | Buy → Hold | — |
- GLMD stock shot up 85% pre-market after rising 27% in 5 days – what’s the latest on its Parkinson’s disease therapy? - MSN Mon, 27 Apr 2026 12
- Galmed says new Aramchol version crosses a barrier that stops 98% of drugs - Stock Titan hu, 09 Apr 2026 07
- Why Is Galmed Pharmaceuticals Stock (GLMD) Up Today? - TipRanks hu, 09 Apr 2026 07
- GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent. - Meet Estimates - Cổng thông tin điện tử tỉnh Tây Ninh Wed, 22 Apr 2026 23
- Galmed Stock Soars On Brain-Penetrating Aramchol Formulation - Galmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga hu, 09 Apr 2026 07
- Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15 - Fast Moving Stocks - Cổng thông tin điện tử Tỉnh Sơn La Wed, 15 Apr 2026 20
- Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire hu, 22 May 2025 07
- Galmed (NASDAQ: GLMD) AM-001 shows 5-fold, 3-fold Aramchol bioavailability improvement - Stock Titan ue, 18 Nov 2025 08
- A brain-penetrating drug will be tested against metastatic brain cancer - Stock Titan ue, 14 Apr 2026 07
- Nasdaq warns Galmed: lift share price above $1 or face delisting - Stock Titan Fri, 30 Jan 2026 08
- [EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing - Stock Titan Wed, 01 Apr 2026 07
- Galmed Pharmaceuticals (GLMD) director Nir Shmuel details initial share and RSU holdings - Stock Titan Wed, 18 Mar 2026 07
- Galmed Pharmaceuticals Sets March 4 Vote on Reverse Stock Split to Address Nasdaq Listing Deficiency - TipRanks Mon, 09 Feb 2026 08
- Is Galmed Pharmaceuticals (GLMD) Stock a Safe Investment | Price at $0.52, Down 1.03% - Bollinger Bands - Xã Vĩnh Công Mon, 06 Apr 2026 07
- Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value - PR Newswire Mon, 25 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
8.51
+35.55%
|
6.28
-16.20%
|
7.49
-57.55%
|
17.65
|
| Research And Development |
|
4.87
+63.61%
|
2.98
-16.53%
|
3.57
-72.54%
|
12.99
|
| Selling General And Administration |
|
3.64
+10.22%
|
3.30
-15.91%
|
3.92
-15.74%
|
4.66
|
| General And Administrative Expense |
|
3.64
+10.22%
|
3.30
-15.91%
|
3.92
-15.74%
|
4.66
|
| Salaries And Wages |
|
2.33
+22.56%
|
1.90
-8.67%
|
2.08
+0.00%
|
2.08
|
| Other Gand A |
|
0.90
+0.33%
|
0.90
-1.32%
|
0.91
-16.24%
|
1.08
|
| Total Expenses |
|
8.51
+35.55%
|
6.28
-16.20%
|
7.49
-57.55%
|
17.65
|
| Operating Income |
|
-8.51
-35.55%
|
-6.28
+16.20%
|
-7.49
+57.55%
|
-17.65
|
| Total Operating Income As Reported |
|
-8.51
-35.55%
|
-6.28
+16.20%
|
-7.49
+57.55%
|
-17.65
|
| EBITDA |
|
-8.51
-37.37%
|
-6.20
+16.97%
|
-7.46
+57.65%
|
-17.62
|
| Normalized EBITDA |
|
-5.89
-16.03%
|
-5.08
+33.85%
|
-7.68
+55.17%
|
-17.13
|
| Reconciled Depreciation |
|
0.00
-100.00%
|
0.08
+167.74%
|
0.03
-11.43%
|
0.04
|
| EBIT |
|
-8.51
-35.55%
|
-6.28
+16.20%
|
-7.49
+57.55%
|
-17.65
|
| Total Unusual Items |
|
-2.62
-134.38%
|
-1.12
-617.13%
|
0.22
+144.08%
|
-0.49
|
| Total Unusual Items Excluding Goodwill |
|
-2.62
-134.38%
|
-1.12
-617.13%
|
0.22
+144.08%
|
-0.49
|
| Special Income Charges |
|
-2.46
-114.93%
|
-1.15
|
0.00
|
0.00
|
| Write Off |
|
2.46
+114.93%
|
1.15
|
0.00
|
0.00
|
| Net Income |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Pretax Income |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Net Non Operating Interest Income Expense |
|
0.82
+771.31%
|
-0.12
-133.52%
|
0.36
+32.36%
|
0.28
|
| Net Interest Income |
|
0.82
+771.31%
|
-0.12
-133.52%
|
0.36
+32.36%
|
0.28
|
| Interest Income Non Operating |
|
0.91
+81.71%
|
0.50
+34.13%
|
0.38
+26.26%
|
0.30
|
| Interest Income |
|
0.91
+81.71%
|
0.50
+34.13%
|
0.38
+26.26%
|
0.30
|
| Other Income Expense |
|
-2.62
-134.38%
|
-1.12
-617.13%
|
0.22
+144.08%
|
-0.49
|
| Gain On Sale Of Security |
|
-0.16
-660.71%
|
0.03
-87.04%
|
0.22
+144.08%
|
-0.49
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Net Income From Continuing And Discontinued Operation |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Net Income Continuous Operations |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Normalized Income |
|
-7.69
-20.17%
|
-6.40
+10.21%
|
-7.13
+58.98%
|
-17.38
|
| Net Income Common Stockholders |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Diluted EPS |
|
-2.39
+70.42%
|
-8.08
+73.07%
|
-30.00
+76.53%
|
-127.80
|
| Basic EPS |
|
-2.39
+70.42%
|
-8.08
+73.07%
|
-30.00
+76.53%
|
-127.80
|
| Basic Average Shares |
|
4.31
+363.17%
|
0.93
+303.31%
|
0.23
+65.23%
|
0.14
|
| Diluted Average Shares |
|
4.31
+363.17%
|
0.93
+303.31%
|
0.23
+65.23%
|
0.14
|
| Diluted NI Availto Com Stockholders |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Insurance And Claims |
|
0.38
-2.83%
|
0.39
-42.54%
|
0.68
-38.12%
|
1.09
|
| Rent And Landing Fees |
|
0.03
-70.94%
|
0.12
-55.17%
|
0.26
-34.91%
|
0.40
|
| Rent Expense Supplemental |
|
0.03
-70.94%
|
0.12
-55.17%
|
0.26
-34.91%
|
0.40
|
| Total Other Finance Cost |
|
0.10
-84.80%
|
0.62
+5581.82%
|
0.01
-50.00%
|
0.02
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
18.63
+0.69%
|
18.50
+11.25%
|
16.63
+0.41%
|
16.56
|
| Current Assets |
|
18.63
+15.52%
|
16.12
+21.79%
|
13.24
-10.09%
|
14.72
|
| Cash Cash Equivalents And Short Term Investments |
|
18.16
+18.43%
|
15.33
+21.27%
|
12.64
-8.29%
|
13.79
|
| Cash And Cash Equivalents |
|
3.98
-14.34%
|
4.65
+62.60%
|
2.86
+41.91%
|
2.02
|
| Other Short Term Investments |
|
14.17
+32.70%
|
10.68
+9.18%
|
9.78
-16.89%
|
11.77
|
| Receivables |
|
0.08
-61.72%
|
0.21
+26.67%
|
0.17
+5.10%
|
0.16
|
| Other Receivables |
|
0.08
-61.72%
|
0.21
+26.67%
|
0.17
+5.10%
|
0.16
|
| Prepaid Assets |
|
0.27
-42.33%
|
0.46
+46.98%
|
0.32
-52.84%
|
0.67
|
| Restricted Cash |
|
0.12
+2.48%
|
0.12
+3.42%
|
0.12
+2.63%
|
0.11
|
| Total Non Current Assets |
|
0.00
-100.00%
|
2.38
-29.91%
|
3.39
+84.54%
|
1.84
|
| Net PPE |
|
—
|
0.00
-100.00%
|
0.12
-62.91%
|
0.34
|
| Gross PPE |
|
—
|
1.10
-3.58%
|
1.14
-13.66%
|
1.32
|
| Accumulated Depreciation |
|
—
|
-1.10
-8.24%
|
-1.02
-3.14%
|
-0.99
|
| Properties |
|
—
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
—
|
0.13
+0.00%
|
0.13
+0.00%
|
0.13
|
| Other Properties |
|
—
|
0.74
-5.39%
|
0.78
-18.85%
|
0.96
|
| Leases |
|
—
|
0.24
+0.43%
|
0.23
+0.00%
|
0.23
|
| Investments And Advances |
|
0.00
-100.00%
|
2.12
-35.10%
|
3.27
+117.67%
|
1.50
|
| Long Term Equity Investment |
|
0.00
-100.00%
|
2.12
-35.10%
|
3.27
|
0.00
|
| Total Liabilities Net Minority Interest |
|
2.85
+30.92%
|
2.17
-20.98%
|
2.75
-12.36%
|
3.14
|
| Current Liabilities |
|
2.85
+30.92%
|
2.17
-20.98%
|
2.75
-11.12%
|
3.09
|
| Payables And Accrued Expenses |
|
2.29
+45.73%
|
1.57
-26.57%
|
2.14
-22.62%
|
2.76
|
| Payables |
|
2.00
+52.59%
|
1.31
-30.07%
|
1.88
-26.80%
|
2.57
|
| Accounts Payable |
|
2.00
+53.13%
|
1.31
-30.39%
|
1.88
-26.60%
|
2.56
|
| Other Payable |
|
0.00
-66.67%
|
0.01
|
—
|
0.01
|
| Current Accrued Expenses |
|
0.28
+10.55%
|
0.26
-1.16%
|
0.26
+32.14%
|
0.20
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.56
-7.63%
|
0.60
+5.60%
|
0.57
+256.88%
|
0.16
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.04
-76.02%
|
0.17
|
| Current Capital Lease Obligation |
|
—
|
0.00
-100.00%
|
0.04
-76.02%
|
0.17
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
0.00
-100.00%
|
0.04
|
| Stockholders Equity |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Common Stock Equity |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Capital Stock |
|
3.41
+359.30%
|
0.74
+255.02%
|
0.21
+198.57%
|
0.07
|
| Common Stock |
|
3.41
+359.30%
|
0.74
+255.02%
|
0.21
+198.57%
|
0.07
|
| Share Issued |
|
6.58
+295.31%
|
1.66
+295.98%
|
0.42
+200.28%
|
0.14
|
| Ordinary Shares Number |
|
6.58
+295.31%
|
1.66
+295.98%
|
0.42
+200.28%
|
0.14
|
| Additional Paid In Capital |
|
223.46
+3.23%
|
216.47
+4.54%
|
207.08
+3.47%
|
200.14
|
| Retained Earnings |
|
-210.78
-5.14%
|
-200.47
-3.90%
|
-192.95
-3.72%
|
-186.04
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.30
+27.16%
|
-0.42
+8.37%
|
-0.45
+39.06%
|
-0.74
|
| Other Equity Adjustments |
|
-0.30
+27.16%
|
-0.42
+8.37%
|
-0.45
+39.06%
|
-0.74
|
| Total Equity Gross Minority Interest |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Total Capitalization |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Working Capital |
|
15.78
+13.12%
|
13.95
+33.01%
|
10.49
-9.81%
|
11.63
|
| Invested Capital |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Total Debt |
|
—
|
0.00
-100.00%
|
0.04
-80.93%
|
0.21
|
| Capital Lease Obligations |
|
—
|
0.00
-100.00%
|
0.04
-80.93%
|
0.21
|
| Net Tangible Assets |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Tangible Book Value |
|
15.78
-3.34%
|
16.33
+17.64%
|
13.88
+3.40%
|
13.42
|
| Available For Sale Securities |
|
—
|
—
|
—
|
1.50
|
| Investmentin Financial Assets |
|
—
|
—
|
0.00
-100.00%
|
1.50
|
| Investmentsin Associatesat Cost |
|
0.00
-100.00%
|
2.12
-35.10%
|
3.27
|
0.00
|
| Non Current Note Receivables |
|
0.00
-100.00%
|
0.26
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-6.32
-7.40%
|
-5.88
+4.19%
|
-6.14
+66.83%
|
-18.50
|
| Cash Flow From Continuing Operating Activities |
|
-6.32
-7.40%
|
-5.88
+4.19%
|
-6.14
+66.83%
|
-18.50
|
| Net Income From Continuing Operations |
|
-10.31
-37.14%
|
-7.52
-8.75%
|
-6.91
+61.31%
|
-17.87
|
| Depreciation Amortization Depletion |
|
0.00
-100.00%
|
0.08
+167.74%
|
0.03
-11.43%
|
0.04
|
| Depreciation |
|
0.00
-100.00%
|
0.08
+167.74%
|
0.03
-11.43%
|
0.04
|
| Depreciation And Amortization |
|
0.00
-100.00%
|
0.08
+167.74%
|
0.03
-11.43%
|
0.04
|
| Other Non Cash Items |
|
-0.02
-103.44%
|
0.61
+1400.00%
|
-0.05
-30.56%
|
-0.04
|
| Stock Based Compensation |
|
0.55
+2.82%
|
0.53
-40.47%
|
0.89
-31.17%
|
1.30
|
| Asset Impairment Charge |
|
2.46
+114.93%
|
1.15
|
0.00
|
0.00
|
| Operating Gains Losses |
|
0.08
+575.00%
|
0.01
-7.69%
|
0.01
-97.51%
|
0.52
|
| Gain Loss On Investment Securities |
|
0.08
+575.00%
|
0.01
-7.69%
|
0.01
-97.51%
|
0.52
|
| Unrealized Gain Loss On Investment Securities |
|
0.00
|
0.00
+100.00%
|
-0.27
|
0.00
|
| Change In Working Capital |
|
0.91
+225.27%
|
-0.73
-651.52%
|
0.13
+105.39%
|
-2.45
|
| Change In Receivables |
|
0.24
+225.00%
|
-0.19
-155.65%
|
0.34
+15.00%
|
0.30
|
| Change In Payables And Accrued Expense |
|
0.67
+225.37%
|
-0.54
-151.64%
|
-0.21
+92.26%
|
-2.75
|
| Change In Payable |
|
0.67
+225.37%
|
-0.54
-151.64%
|
-0.21
+92.26%
|
-2.75
|
| Change In Account Payable |
|
0.69
+221.72%
|
-0.57
+16.15%
|
-0.68
+70.53%
|
-2.31
|
| Change In Other Working Capital |
|
—
|
0.01
+113.21%
|
-0.05
|
—
|
| Investing Cash Flow |
|
-3.38
-203.78%
|
-1.11
-238.88%
|
0.80
-95.44%
|
17.56
|
| Cash Flow From Continuing Investing Activities |
|
-3.38
-203.78%
|
-1.11
-238.88%
|
0.80
-95.44%
|
17.56
|
| Net PPE Purchase And Sale |
|
—
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Purchase Of PPE |
|
—
|
0.00
|
0.00
+100.00%
|
-0.00
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.00
|
| Net Investment Purchase And Sale |
|
-3.38
-291.99%
|
-0.86
-137.43%
|
2.30
-86.91%
|
17.57
|
| Purchase Of Investment |
|
-4.99
+21.67%
|
-6.37
-0.51%
|
-6.33
-63.52%
|
-3.87
|
| Sale Of Investment |
|
1.61
-70.73%
|
5.50
-36.24%
|
8.63
-59.73%
|
21.44
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
+100.00%
|
-1.50
|
0.00
|
| Purchase Of Business |
|
0.00
|
0.00
+100.00%
|
-1.50
|
0.00
|
| Net Other Investing Changes |
|
—
|
-0.25
|
—
|
—
|
| Financing Cash Flow |
|
9.03
+2.73%
|
8.79
+42.05%
|
6.18
+8735.71%
|
0.07
|
| Cash Flow From Continuing Financing Activities |
|
9.03
+2.73%
|
8.79
+42.05%
|
6.18
+8735.71%
|
0.07
|
| Net Common Stock Issuance |
|
9.03
+2.73%
|
8.79
+42.05%
|
6.18
+8735.71%
|
0.07
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
|
0.00
|
| Changes In Cash |
|
-0.66
-136.99%
|
1.79
+111.67%
|
0.85
+197.70%
|
-0.87
|
| Beginning Cash Position |
|
4.77
+60.28%
|
2.98
+39.81%
|
2.13
-28.95%
|
3.00
|
| End Cash Position |
|
4.11
-13.91%
|
4.77
+60.28%
|
2.98
+39.81%
|
2.13
|
| Free Cash Flow |
|
-6.32
-7.40%
|
-5.88
+4.19%
|
-6.14
+66.84%
|
-18.50
|
| Amortization Of Securities |
|
0.01
+188.24%
|
-0.02
-189.47%
|
0.02
+1050.00%
|
-0.00
|
| Common Stock Issuance |
|
9.03
+2.73%
|
8.79
+42.05%
|
6.18
+8735.71%
|
0.07
|
| Earnings Losses From Equity Investments |
|
—
|
-0.01
|
0.00
|
0.00
|
| Issuance Of Capital Stock |
|
9.03
+2.73%
|
8.79
+42.05%
|
6.18
+8735.71%
|
0.07
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|